Novo Nordisk to halve US list price of Wegovy from 2027

Novo Nordisk said it will cut U.S. list prices for Wegovy and Ozempic by up to 50%, with the reductions scheduled to start in 2027, the company announced.

Novo Nordisk said it will reduce U.S. list prices for Wegovy and Ozempic by up to 50% starting in 2027. The Danish drugmaker made the announcement on Tuesday. Both medicines are used for diabetes and weight management and have been described as blockbusters in recent years. The company framed the change as an adjustment to published list prices. Key details: - Novo Nordisk announced U.S. list price reductions of up to 50% for Wegovy and Ozempic. - The price changes are scheduled to take effect in 2027, described in the company statement as "starting next year." - The announcement was made on a Tuesday and reported by the news outlet. - Both drugs are indicated for diabetes and weight-related treatment and have seen strong sales in recent years. Summary: The announcement changes the published list prices for two widely used treatments in the U.S. and is set to take effect in 2027. Further details on implementation, reimbursement implications, or broader timing were not provided in the report.